|
|
HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $11 Price Target
|
|
|
|
12 Health Care Stocks Moving In Wednesday's Intraday Session
|
|
|
|
MannKind Enrolls The First Patient In INHALE-1ST Clinical Study Evaluating Afrezza (Insulin Human) Inhalation Powder Shortly After Type 1 Diabetes Diagnosis In Pediatric Patients
|
|
|
|
HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $11 Price Target
|
|
|
|
The FDA Approves An Update To Prescribing Information For MannKind's Afrezza (Insulin Human) Inhalation Powder, Revising Recommendations For Starting Mealtime Dosage When Patients Switch From Subcutaneous Mealtime Insulin Regimens
|
|